West Pharmaceutical Services, Inc.
WST Healthcare Medical Instruments & Supplies
West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024.
- Revenue
- +8.69%
- EPS
- +56.7%
- Free cash flow
- +12.3%
- Total debt
- +0.10%
Quarter to September 2026, against a year earlier
Follow WST
Alert me
West Pharmaceutical Services, Inc. (WST) EV/EBITDA
As of 5 November 2026, West Pharmaceutical Services, Inc. (WST) trades at a EV/EBITDA of 28.4×. Over the past ten years it has ranged from 13.0× (February 2015) to 47.9× (September 2021); the current reading is higher than 64% of that period. That is above the Medical Instruments & Supplies industry median of 14.9× and above the Healthcare sector median of 8.4×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 25.5× | (21.66%) |
| FY2024 | 32.6× | 5.45% |
| FY2023 | 30.9× | 57.60% |
| FY2022 | 19.6× | (50.08%) |
| FY2021 | 39.3× | (1.52%) |
| FY2020 | 39.9× | 45.78% |
| FY2019 | 27.4× | 32.73% |
| FY2018 | 20.6× | (9.14%) |
| FY2017 | 22.7× | 4.83% |
| FY2016 | 21.6× | 10.19% |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 26.8× | (8.32%) |
| Jun 2026 | 29.2× | 37.09% |
| Mar 2026 | 21.3× | (16.48%) |
| Dec 2025 | 25.5× | 3.81% |
| 43 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| MDLN Medline Inc. compare | 4.5× |
| SOLV Solventum Corporation compare | 7.6× |
| ALGN Align Technology, Inc. compare | 12.6× |
| BAX Baxter International Inc. compare | 13.2× |
| ALC Alcon compare | 14.8× |
| BDX Becton, Dickinson and Company compare | 14.9× |
| RMD ResMed Inc. compare | 15.7× |
| COO The Cooper Companies, Inc. compare | 15.8× |
| WST West Pharmaceutical Services, Inc. | 28.4× |
| Medical Instruments & Supplies industry median | 14.9× |
| Healthcare sector median | 8.4× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on WST
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement